Skip to content
Reipet – Lifestyle
Author:
Ambrosia Biosciences
Ambrosia Biosciences Enhances Clinical and Scientific Expertise with Chief Medical Officer and Scientific Advisory Board Appointments
July 28, 2026
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
June 5, 2026
Ambrosia Biosciences Announces Late-Breaking Poster Presentation at the American Diabetes Association’s (ADA) 86th Scientific Session
April 21, 2026
Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline
March 31, 2026